Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus

被引:39
作者
Lee, AB
Godfrey, T
Rowley, KG
Karschimkus, CS
Dragicevic, G
Romas, E
Clemens, L
Wilson, AM
Nikpour, M
Prior, DL
Best, JD
Jenkins, AJ
机构
[1] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia
[2] Univ Melbourne, St Vincents Hosp, Dept Rheumatol, Melbourne, Vic, Australia
关键词
systemic lupus erythematosus; vascular health; novel vascular disease risk factors; arterial elasticity; impaired endothelial function;
D O I
10.1111/j.1445-5994.2006.01044.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Systemic lupus erythematosus (SLE) is associated with accelerated atherosclerosis. However, the degree of endothelial dysfunction and its relationship to traditional and novel cardiovascular risk factors have not been examined in SLE. Methods: In a case-control design, 35 patients with clinically stable SLE and 35 control subjects matched for age, sex, body mass index and smoking status were studied. Arterial elasticity, lipid profile, homocysteine, measures of inflammation and oxidative stress were determined. Results: Among traditional vascular risk factors, there was a nonsignificant trend towards lower blood pressure in the control subjects, whereas low-density lipoprotein (LDL) cholesterol levels were significantly lower in the SLE group (2.5 vs 3.3 mmol/L, P < 0.001). Patients with SLE had significantly lower small artery elasticity (SAE; 4.9 vs 7.0 ml/mmHg x 100, P < 0.001) and higher plasma homocysteine (11.4 vs 8.3 mmol/L, P=0.002) than control subjects. Levels of serum sVCAM-1 (614 vs 494 ng/mL, P=0.002), oxidized LDL (144 vs 97, P < 0.001) and CD40 ligand (4385 vs 1373 pg/ml, P=0.001) were significantly higher in SLE. Oxidized LDL levels, older age at SLE diagnosis and higher disease damage scores correlated inversely with SAE but not traditional risk factors. Conclusion: Impaired endothelial function as shown by decreased SAE, and an adverse profile of novel proatherogenic and prothrombotic vascular disease risk factors were prevalent in clinically quiescent SLE. These findings show the vulnerability of patients with SLE for atherosclerosis, and emphasize that assessments based on traditional risk factors alone may be inadequate.
引用
收藏
页码:237 / 243
页数:7
相关论文
共 27 条
[1]   Premature coronary-artery atherosclerosis in systemic lupus erythematosus [J].
Asanuma, Y ;
Oeser, A ;
Shintani, AK ;
Turner, E ;
Olsen, N ;
Fazio, S ;
Linton, MF ;
Raggi, P ;
Stein, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2407-2415
[2]   Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation [J].
Bin Ali, A ;
Zhang, Q ;
Lim, YK ;
Fang, D ;
Retnam, L ;
Lim, SK .
FREE RADICAL BIOLOGY AND MEDICINE, 2003, 34 (07) :824-829
[3]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[4]  
DELGADO AJ, 2002, ARTHRITIS RHEUM, V46, P2686, DOI DOI 10.1371/JOURNAL.PONE.0186513
[5]   Systemic lupus erythematosus - An independent risk factor for endothelial dysfunction in women [J].
El-Magadmi, M ;
Bodill, H ;
Ahmad, Y ;
Durrington, PN ;
Mackness, M ;
Walker, M ;
Bernstein, RM ;
Bruce, IN .
CIRCULATION, 2004, 110 (04) :399-404
[6]  
Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO
[7]  
2-I
[8]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[9]   Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease [J].
Holvoet, P ;
Mertens, A ;
Verhamme, P ;
Bogaerts, K ;
Beyens, G ;
Verhaeghe, R ;
Collen, D ;
Muls, E ;
Van de Werf, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (05) :844-848
[10]   The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia [J].
Kural, BV ;
Örem, C ;
Uydu, HA ;
Alver, A ;
Örem, A .
CORONARY ARTERY DISEASE, 2004, 15 (05) :277-283